{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T22:25:43Z","timestamp":1752359143334},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,9]]},"DOI":"10.7759\/cureus.60004","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:00:30Z","timestamp":1715313630000},"source":"Crossref","is-referenced-by-count":1,"title":["Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease"],"prefix":"10.7759","author":[{"given":"Jose Carlos D","family":"Saballegue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma. Luisa Gwenn P","family":"Tiongson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor JY","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I, et al.. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020, 11:501. 10.3389\/fneur.2020.00501","journal-title":"Front Neurol"},{"key":"ref2","article-title":"Comparison of clinical features between aquaporin-4 antibody seropositive and seronegative patients in neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"23","author":"Kunadison S","year":"2018","unstructured":"Kunadison S, Tungkasereerak C, Saetang S, Mekawichai P. Comparison of clinical features between aquaporin-4 antibody seropositive and seronegative patients in neuromyelitis optica and neuromyelitis optica spectrum disorder. Neurol Asia. 2018, 23:55-9.","journal-title":"Neurol Asia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2018.02.084","article-title":"Neuromyelitis optica spectrum disorders: features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes","volume":"174","author":"Alves Do Rego C","year":"2018","unstructured":"Alves Do Rego C, Collongues N. Neuromyelitis optica spectrum disorders: features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Rev Neurol (Paris). 2018, 174:458-70. 10.1016\/j.neurol.2018.02.084","journal-title":"Rev Neurol (Paris)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.922590","article-title":"Seronegative neuromyelitis optica spectrum disorder: an unusual presentation of acute brainstem syndrome","volume":"21","author":"Alshurafa ZH","year":"2020","unstructured":"Alshurafa ZH, Alkhateeb MO. Seronegative neuromyelitis optica spectrum disorder: an unusual presentation of acute brainstem syndrome. Am J Case Rep. 2020, 21:e922590-1-4. 10.12659\/AJCR.922590","journal-title":"Am J Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103757","article-title":"Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report","volume":"78","author":"Khadka B","year":"2022","unstructured":"Khadka B, Bhattarai AM, Dhakal B, Karki A, Acharya A, Poudel R. Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report. Ann Med Surg (Lond). 2022, 78:103757. 10.1016\/j.amsu.2022.103757","journal-title":"Ann Med Surg (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk DM","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-15. 10.1016\/S1474-4422(07)70216-8","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim HJ","year":"2015","unstructured":"Kim HJ, Paul F, Lana-Peixoto MA, et al.. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015, 84:1165-73. 10.1212\/WNL.0000000000001367","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron J","year":"2018","unstructured":"Ciron J, Audoin B, Bourre B, et al.. Recommendations for the use of rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018, 174:255-64. 10.1016\/j.neurol.2017.11.005","journal-title":"Rev Neurol (Paris)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/1735-1995.200275","article-title":"Efficacy and safety of rituximab in neuromyelitis optica: review of evidence","volume":"22","author":"Etemadifar M","year":"2017","unstructured":"Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M, Fayyazi E. Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci. 2017, 22:18. 10.4103\/1735-1995.200275","journal-title":"J Res Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy M","year":"2021","unstructured":"Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021, 20:60-7. 10.1016\/S1474-4422(20)30392-6","journal-title":"Lancet Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241771-rituximab-therapy-for-double-seronegative-neuromyelitis-optica-spectrum-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:00:36Z","timestamp":1715313636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241771-rituximab-therapy-for-double-seronegative-neuromyelitis-optica-spectrum-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.60004","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}